MiNK Therapeutics, Inc.
INKT
$8.41
-$0.34-3.89%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -30.45% | 9.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -134.66% | -- | |||
| Total Operating Expenses | 131.74% | -35.05% | |||
| Operating Income | -131.74% | 35.05% | |||
| Income Before Tax | -36.34% | 33.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -36.34% | 33.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -36.34% | 33.13% | |||
| EBIT | -131.74% | 35.05% | |||
| EBITDA | -133.79% | 36.22% | |||
| EPS Basic | -36.21% | 37.17% | |||
| Normalized Basic EPS | -126.93% | 41.21% | |||
| EPS Diluted | -172.80% | 37.17% | |||
| Normalized Diluted EPS | -126.93% | 41.21% | |||
| Average Basic Shares Outstanding | 0.09% | 6.44% | |||
| Average Diluted Shares Outstanding | 0.09% | 6.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
